Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned an average rating of “Buy” from the thirty-three research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $85.52.

Several equities research analysts recently commented on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a research note on Wednesday, September 6th. Morgan Stanley restated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th.

Shares of Gilead Sciences (GILD) traded down 0.243% during trading on Wednesday, hitting $80.045. 4,236,213 shares of the company were exchanged. The stock has a market capitalization of $104.53 billion, a PE ratio of 8.694 and a beta of 1.14. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a 50 day moving average of $82.48 and a 200-day moving average of $72.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period last year, the company earned $3.08 EPS. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts forecast that Gilead Sciences will post $8.73 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

WARNING: “Gilead Sciences, Inc. (GILD) Given Consensus Recommendation of “Buy” by Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/18/gilead-sciences-inc-gild-given-consensus-recommendation-of-buy-by-brokerages.html.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last three months, insiders have sold 486,819 shares of company stock worth $39,298,919. Corporate insiders own 1.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its holdings in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Webster Bank N. A. lifted its holdings in shares of Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the period. American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences in the 1st quarter worth $143,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth $147,000. 73.97% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.